deepeye Medical GmbH

deepeye Medical is a Munich-based health technology company dedicated to preventing avoidable blindness caused by retinal diseases. The company has developed an AI-based precision medicine platform designed to assist ophthalmologists in optimizing therapy planning for conditions such as neovascular age-related macular degeneration (nAMD). By analyzing optical coherence tomography (OCT) scans, the platform provides a "second opinion" that predicts disease progression and individual treatment needs, aiming to improve patient outcomes significantly.

The core technology, deepeye TPS (Therapy Planning Support), is a CE-marked Class IIa medical device that integrates seamlessly into clinical workflows. It leverages deep learning algorithms trained on a vast dataset of real-world patient cases to offer actionable insights, such as optimal injection intervals and disease activity assessments. This approach addresses the critical issue of undertreatment and patient dropout in retinal therapy, which are major contributors to vision loss. Clinical validations have demonstrated that the platform can triple visual acuity gains and double therapy adherence compared to standard care.

Founded in 2021, deepeye Medical collaborates with leading pharmaceutical companies, research institutions, and medical device manufacturers to scale its impact globally. The company's mission is to save one million people from blindness by 2030 by empowering eye care professionals with predictive, data-driven tools that enable personalized and proactive treatment strategies.